Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection
What symptoms are differentially present in SARS-CoV-2–infected individuals 6 months or more after infection compared with uninfected individuals? What symptom-based criteria can be used to identify postacute sequelae of SARS-CoV-2 infection cases?
Diagnosis of type 1 diabetes after SARS-CoV-2 infection: Researchers find possible correlation
Researchers at Helmholtz Munich and TU Dresden, in cooperation with the Kassenärztliche Vereinigung Bayern, have now investigated whether there is a temporal association between infection with the SARS-CoV-2 virus and the development of type 1 diabetes.
Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers
Antibody levels and neutralizing activity progressively increased with each booster but subsequently waned over 3-6 months.
The impact of the SARS-CoV-2 pandemic on global influenza surveillance: Insights from 18 National Influenza Centers based on a survey conducted between November 2021 and March 2022
National Influenza Centers have played a crucial role in the surveillance of SARS-CoV-2. The FluCov project, covering 22 countries, was initiated to monitor the impact of the SARS-CoV-2 pandemic on influenza activity.
Influenza Vaccines: What Does the mRNA Platform Have to Offer?
Are you up to date about current developments in influenza vaccines with the messenger RNA (mRNA) platform?
Reaching for New Heights: Breaking Down Influenza Trends and Prevention Efforts
Did you know that in female children, influenza pneumonia is the second most common cause of death?
Prevention of long COVID: progress and challenges
Long COVID—the umbrella term that encompasses the post-acute and long-term sequelae of SARS-CoV-2 infection—can be profoundly disabling and might affect people for a lifetime.
Algorithm for Optimised mRNA Design Improves Stability and Immunogenicity
mRNA vaccines are being used to contain COVID-19, but still suffer from the critical limitation of mRNA instability and degradation, which is a major obstacle in the storage, distribution, and efficacy of the vaccine products.
ReSViNET's RSV Dashboard is 𝐋𝐈𝐕𝐄!
ReSViNET Foundation is supporting healthcare decisions by providing transparency and accessibility to shared global RSV surveillance data. The dashboard will help simplify tracking changes in RSV seasonality globally.
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
RSV infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown.
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
Whether vaccination during pregnancy could reduce the burden of RSV associated lower respiratory tract illness in newborns and infants is uncertain.
Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study
Early-life severe RSV infection has been associated with the onset of childhood wheezing illnesses. However, the relationship between RSV infection during infancy and the development of childhood asthma is unclear.